Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov 27;11(12):1889.
doi: 10.3390/cancers11121889.

Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model

Carla De Giovanni  1 , Giordano Nicoletti  2 , Lorena Landuzzi  2 , Arianna Palladini  1 , Pier-Luigi Lollini  1 , Patrizia Nanni  1
Affiliations
Review

Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model

Carla De Giovanni et al. Cancers (Basel). .

Abstract

The TS/A cell line was established in 1983 from a spontaneous mammary tumor arisen in an inbred BALB/c female mouse. Its features (heterogeneity, low immunogenicity and metastatic ability) rendered the TS/A cell line suitable as a preclinical model for studies on tumor-host interactions and for gene therapy approaches. The integrated biological profile of TS/A resulting from the review of the literature could be a path towards the description of a precision experimental model of mammary cancer.

Keywords: TS/A; gene therapy; immunotherapy; metastases; murine mammary cancer; preclinical models.

PubMed Disclaimer

Conflict of interest statement

The University of Bologna granted to EMD Millipore license for TS/A distribution worldwide. Royalties are destined for oncological research.

Figures

Figure 1
Figure 1
Origin of the TS/A cell line and variants. For pictures see [51].
Figure 2
Figure 2
Morphology of the TS/A cell line in adherent culture (phase contrast, ×100).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Letai A. Functional precision cancer medicine-moving beyond pure genomics. Nat. Med. 2017;23:1028–1035. doi: 10.1038/nm.4389. - DOI - PubMed
    1. Gould S.E., Junttila M.R., De Sauvage F.J. Translational value of mouse models in oncology drug development. Nat. Med. 2015;21:431–439. doi: 10.1038/nm.3853. - DOI - PubMed
    1. Heppner G.H., Miller F.R., Shekhar P.V.M. Nontransgenic models of breast cancer. Breast Cancer Res. 2000;2:331–334. doi: 10.1186/bcr77. - DOI - PMC - PubMed
    1. Gengenbacher N., Singhal M., Augustin H.G. Preclinical mouse solid tumour models: Status quo, challenges and perspectives. Nat. Rev. Cancer. 2017;17:751–765. doi: 10.1038/nrc.2017.92. - DOI - PubMed
    1. Haynes B., Sarma A., Nangia-Makker P., Shekhar M.P. Breast cancer complexity: Implications of intratumoral heterogeneity in clinical management. Cancer Metastasis Rev. 2017;36:547–555. doi: 10.1007/s10555-017-9684-y. - DOI - PMC - PubMed